By now, you’ve almost certainly heard of Ozempic. Maybe Wegovy too. And if you’ve been digging deeper into weight loss medications, Mounjaro and Zepbound have probably come up as well.
These four drugs dominate conversations about GLP-1 medications — but they’re not the same thing, they’re not all approved for the same purpose, and they don’t all produce the same results. Choosing the wrong one (or misunderstanding what you’re even taking) can mean spending hundreds of dollars a month on a medication that isn’t the best fit for your goals.
This guide breaks down all four drugs clearly — what they are, how they work, how much weight loss to expect, what they cost, what the side effects are, and most importantly: which one might be right for you.
Important: This article is for informational purposes only. Always consult your doctor or healthcare provider before starting, stopping, or changing any medication.
First, the Big Picture: Two Drugs, Four Brand Names
Here’s the thing that confuses most people: there are really only two active ingredients behind all four drugs.
| Brand Name | Active Ingredient | Made By | FDA-Approved For |
|---|---|---|---|
| Ozempic | Semaglutide | Novo Nordisk | Type 2 diabetes + cardiovascular risk |
| Wegovy | Semaglutide | Novo Nordisk | Chronic weight management (obesity) |
| Mounjaro | Tirzepatide | Eli Lilly | Type 2 diabetes |
| Zepbound | Tirzepatide | Eli Lilly | Chronic weight management (obesity) |
In simple terms: Ozempic and Wegovy are the same molecule at different doses, approved for different conditions. The same is true for Mounjaro and Zepbound. So the real competition is semaglutide vs. tirzepatide — and that’s where it gets interesting.
How Do They Work?
All four medications belong to a class called GLP-1 receptor agonists — drugs that mimic a natural gut hormone (GLP-1) that your body releases after eating. This hormone signals your brain that you’re full, slows digestion, and helps regulate blood sugar.
The key difference: Mounjaro and Zepbound (tirzepatide) also activate a second hormone receptor called GIP, in addition to GLP-1. This dual mechanism — targeting both GLP-1 and GIP receptors — is why tirzepatide generally produces more weight loss than semaglutide alone.
- Semaglutide (Ozempic / Wegovy): GLP-1 receptor agonist only
- Tirzepatide (Mounjaro / Zepbound): GLP-1 and GIP receptor agonist (dual action)
Weight Loss Results: How Much Can You Expect?
This is where the drugs differ most meaningfully. Here’s what clinical trials show:
| Drug | Average Weight Loss | Trial / Notes |
|---|---|---|
| Ozempic | ~6–9 lbs (diabetes patients) | SUSTAIN program; lower dose than Wegovy |
| Wegovy | ~15% of body weight | STEP trials over 68 weeks |
| Wegovy HD (7.2mg) | ~20.7% of body weight | STEP UP trial (FDA approved March 2026) |
| Mounjaro / Zepbound | ~15–22.5% of body weight | SURMOUNT-1; up to 22.5% at highest dose |
A major head-to-head study (SURMOUNT-5) confirmed that tirzepatide outperformed semaglutide directly — patients were up to three times more likely to lose 15% of their body weight on Mounjaro compared to Ozempic or Wegovy.
However, the gap has narrowed in 2026. The newly approved Wegovy HD (high-dose, 7.2mg) produced 20.7% weight loss — nearly matching tirzepatide’s 20.2% in the same trial period. The drugs are now much closer in effectiveness, and the choice increasingly comes down to side effects, cost, and insurance coverage.
💡 Key takeaway: If maximum weight loss is your top priority, tirzepatide (Mounjaro/Zepbound) still has a slight edge. But the new high-dose Wegovy is closing the gap fast.
Side Effects: What to Expect
All four drugs share a similar side effect profile because they all work on the GLP-1 pathway. Most side effects are gastrointestinal and tend to be worst when you first start or increase your dose.
Common side effects (all four drugs):
- Nausea (most common, especially early on)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort or bloating
- Reduced appetite (often a desired effect)
Rare but serious risks:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder disease
- Kidney issues (usually related to dehydration from vomiting/diarrhea)
- Possible thyroid tumor risk — these drugs carry a black box warning for patients with a personal or family history of medullary thyroid cancer or MEN2 syndrome
- Gastroparesis (slowed stomach emptying) — a more serious concern that has led to lawsuits
Tirzepatide (Mounjaro/Zepbound) may cause slightly more nausea and vomiting during the first 4–8 weeks compared to semaglutide, due to its dual mechanism — but most patients tolerate it well once their body adjusts. Doses are always started low and increased gradually to minimize side effects.
Cost in 2026: What You’ll Actually Pay
Cost remains one of the biggest barriers to access for these medications. Here’s a realistic picture:
| Drug | List Price (without insurance) | Self-Pay / Savings Options |
|---|---|---|
| Ozempic | ~$900–$1,000/month | From $199/month (new patients, introductory offer) |
| Wegovy | ~$1,300–$1,400/month | From $349/month self-pay; $199 first 2 months |
| Mounjaro | ~$900–$1,000/month | Savings cards available through Eli Lilly |
| Zepbound | ~$550–$650/month (vial) | $349–$499/month through Eli Lilly direct program |
Prices are coming down. The Trump administration announced a deal with Eli Lilly and Novo Nordisk to lower consumer prices through a new direct-to-consumer platform (TrumpRx). Under this program, Ozempic, Wegovy, and Zepbound are expected to be available for approximately $350 per month. A potential oral GLP-1 pill (orforglipron, pending FDA approval) could be as low as $150/month.
Insurance Coverage: The Complicated Truth
- Ozempic and Mounjaro are generally covered by insurance when prescribed for type 2 diabetes. Coverage for weight loss alone is much less common.
- Wegovy and Zepbound (the weight loss versions) have variable coverage. Some commercial plans cover them; many don’t. Always check your specific formulary.
- Medicare currently does not cover these drugs for weight loss alone, though this may change. They are covered for diabetes and cardiovascular risk reduction.
- Medicaid may cover Ozempic or Mounjaro for diabetes depending on your state.
- Tricare (military) may cover Wegovy and Zepbound with prior authorization if you meet certain criteria.
💡 Tip: GoodRx often offers significant discounts on these medications. For new patients, introductory pricing of $199/month for the first two fills of Ozempic or Wegovy is available through GoodRx or directly from NovoCare (Novo Nordisk’s savings program).
Who Is Each Drug Right For?
Ozempic — Best for: Type 2 Diabetes Management
If you have type 2 diabetes and your primary goal is better blood sugar control, Ozempic is likely your doctor’s first choice. Weight loss is a welcome side benefit, but it’s more modest than what Wegovy produces because the dose is lower. Insurance coverage for diabetes use is also typically the strongest with Ozempic.
Wegovy — Best for: Weight Loss (Semaglutide, Well-Studied)
Wegovy is specifically approved for chronic weight management in adults with a BMI of 30+ (obesity) or 27+ with at least one weight-related condition (like high blood pressure or sleep apnea). It’s the most studied GLP-1 for weight loss in non-diabetic patients. The new high-dose version (Wegovy HD, 7.2mg) now rivals tirzepatide for results. Good choice for patients who want a well-established medication with wide clinical data.
Mounjaro — Best for: Type 2 Diabetes + More Aggressive Weight Loss
Mounjaro is FDA-approved only for type 2 diabetes, but its dual GLP-1/GIP mechanism makes it significantly more powerful for weight loss than Ozempic. Many physicians prescribe it off-label for weight loss in patients with obesity. If you have both diabetes and significant weight to lose, Mounjaro is often considered the stronger option.
Zepbound — Best for: Maximum Weight Loss (Tirzepatide)
Zepbound is the weight-loss approved version of Mounjaro — same drug, same mechanism, but specifically indicated for obesity. Clinical trials show it produces some of the highest weight loss of any prescription medication currently available, with about 20%+ average body weight reduction at the highest dose, and 36% of patients losing 25% or more of their body weight. If maximum weight loss results are your goal and cost or insurance isn’t a barrier, Zepbound is currently among the most powerful options available.
Quick Comparison: Which One Is Right for You?
| Your Goal / Situation | Consider |
|---|---|
| Type 2 diabetes, want insurance coverage | Ozempic or Mounjaro |
| Weight loss, want well-studied semaglutide | Wegovy (or Wegovy HD for more results) |
| Maximum weight loss results | Zepbound or Wegovy HD |
| Type 2 diabetes + significant weight to lose | Mounjaro (possibly off-label for weight) |
| Concerned about side effects / sensitivity | Start with Ozempic or Wegovy (lower dose titration) |
| Budget-conscious, no insurance coverage | Zepbound vials or GoodRx / manufacturer savings programs |
Important Things to Know Before Starting Any GLP-1
- These are long-term medications. Weight often returns when you stop taking them. Most patients who see results continue treatment indefinitely, which makes cost a major long-term consideration.
- They work best alongside lifestyle changes. Diet and exercise amplify results significantly. These drugs are tools, not complete solutions.
- Dose escalation takes time. You start at the lowest dose and increase gradually over weeks or months. Full results aren’t seen immediately.
- Not everyone qualifies. You’ll need a BMI of 30+ (or 27+ with a qualifying condition) for weight loss approval. Patients with certain thyroid conditions or a history of pancreatitis may not be eligible.
- You can switch drugs. If one isn’t working well or side effects are intolerable, doctors can transition you to another. Moving from Ozempic to Mounjaro, for example, typically means restarting at the lowest dose due to the different mechanism.
Bottom Line
Ozempic, Wegovy, Mounjaro, and Zepbound are all legitimate, clinically proven medications — but they’re not interchangeable. The right choice depends on your medical history, your primary goal (diabetes control vs. weight loss), your side effect tolerance, and your insurance coverage.
If you’re primarily managing type 2 diabetes: start with Ozempic or Mounjaro. If weight loss is your primary goal: Wegovy or Zepbound are purpose-built for that. And if you want the most aggressive results currently available by prescription: Zepbound and the new high-dose Wegovy are now neck and neck at the top.
The most important step? Have an honest conversation with your doctor about your goals, your health history, and what your insurance will actually cover. The best GLP-1 drug is the one you can afford, tolerate, and stick with long term.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, changing, or stopping any medication.
